Company Overview
Equillium, Inc. operates as a clinical-stage biotechnology entity dedicated to developing therapeutics for severe autoimmune and inflammatory, or immuno-inflammatory disorders that present unmet medical needs within the United States. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, which typically focuses on high-risk research and development phases before generating significant commercial revenue. Equillium, Inc. currently lists under the ticker symbol EQ and holds a market capitalization of $125.44M, supported by an annual revenue stream of $4.39M and an operational workforce of 35 employees. These financial metrics indicate that the company remains a small-cap entity with limited revenue generation relative to its market valuation, a common characteristic for clinical-stage biotechs that have not yet achieved commercial product milestones.
Financial Health
The company reported revenue of $4.39M over the trailing twelve months, yet this revenue was associated with a net income of $-24,417,000 and an EBITDA of $-24,242,000. The substantial gap between the modest revenue figure and the significant net loss reveals a cost structure heavily driven by research and development expenses rather than operational overhead or cost of goods sold. This disparity suggests that the majority of costs incurred are capital-intensive investments in clinical trials and scientific discovery typical of early-stage biopharmaceutical development. Free cash flow stands at $-13,356,250, indicating that the company is burning cash to fund its operations and development pipeline without generating positive cash flow from trading activities. Despite the negative cash burn, the company maintains a cash balance of $33.12M against total debt of $745,000, providing a liquidity buffer to sustain operations. The balance sheet appears leveraged relative to equity, as evidenced by a debt-to-equity ratio of 2.41, yet the low absolute debt level mitigates immediate refinancing risks. Liquidity is exceptionally strong, highlighted by a current ratio of 10.85, which signifies an ability to cover short-term obligations more than ten times over with current assets. Return metrics reflect the developmental stage, with a return on equity of -90.2% and a return on assets of -44.2%, indicating that management is currently destroying shareholder value per dollar invested while building a platform for future potential.
Valuation Assessment
Equillium, Inc. presents a trailing P/E ratio that is not applicable due to losses, while the forward P/E is listed as -8.03, implying that the market does not anticipate immediate profitability based on current earnings trends. The price-to-book ratio is 4.04, suggesting that the market values the company at a significant premium over its net asset value, likely due to the perceived value of its intellectual property and pipeline assets. Alternative valuation metrics include a price-to-sales ratio of 28.56 and an EV/EBITDA of -3.84, which further highlight that traditional multiple-based valuations are skewed by negative earnings and high revenue multiples common in biotech. The stock has traded between a 52-week high of $2.70 and a 52-week low of $0.27, with the current market price situated at a level that reflects high volatility and speculative pricing relative to the historical range. The beta value of 1.83 indicates that the stock's price volatility is significantly higher than the broader market, moving nearly twice as much as the S&P 500 in response to market swings.
Growth & Income
The company reports revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, reflecting the absence of a commercial sales history and the inability to calculate percentage growth rates without prior comparable periods. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning that no portion of earnings is distributed to shareholders. Instead of paying dividends, the company retains all earnings and reinvests its capital, including its cash reserves, into research, development, and clinical trials to advance its lead product candidate. The overall growth and income profile is characterized by zero current income generation and reliance on external capital or cash reserves to fund future expansion until the therapeutic products reach commercialization milestones.